<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00468832</url>
  </required_header>
  <id_info>
    <org_study_id>UCD0305</org_study_id>
    <nct_id>NCT00468832</nct_id>
  </id_info>
  <brief_title>Longitudinal Study of the Natural History of Duchenne Muscular Dystrophy (DMD)</brief_title>
  <official_title>Longitudinal Study of the Relationship Between Impairment, Activity Limitation, Participation and Quality of Life in Persons With Confirmed Duchenne Muscular Dystrophy (DMD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cooperative International Neuromuscular Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>U.S. Department of Education</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Parent Project Muscular Dystrophy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cooperative International Neuromuscular Research Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to establish the largest long-term assessment of people with
      Duchenne muscular dystrophy (DMD). In this study, the investigators associated with the
      Cooperative International Neuromuscular Research Group CINRG) will take a detailed look (for
      a minimum of eight years) at DMD participant's physical abilities, the medical problems they
      experience, and how they use health care services. Physical abilities will be compared to a
      group of healthy controls.

      The second purpose of this study is to find out whether small, normal differences in the
      genetic makeup of people with DMD (called &quot;single nucleotide polymorphisms&quot; or &quot;SNPs&quot;) affect
      how their disease progresses and relates to muscle strength/size and steroid response.

      The third purpose of this study is to study genetic variations associated with DMD.

      The final purpose of this study is to determine whether certain biomarkers are present in
      people with DMD and not in healthy controls.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phenotyping Study Aims

      Aim 1: Longitudinally assess body function and body structure (impairment) through the
      measurement of anthropometrics, muscle strength and pulmonary function in subjects with DMD
      through the multicenter CINRG network.

      Aim 2: Longitudinally assess activity limitations in subjects with DMD through CINRG with
      timed motor performance, burden of care, and functional status.

      Aim 3: Longitudinally assess secondary conditions in subjects with DMD, and relative risks of
      developing those conditions based on exposure to preventive interventions.

      Aim 4: Longitudinally assess participation, life satisfaction, service utilization and
      health-related quality of life in subjects with DMD.

      Aim 5: Determine appropriate outcome measurements for impairment, activities (activity
      limitations), participation and quality of life to determine the effect of prednisone and
      other therapeutic interventions on these factors.

      Aim 6: Using the most robust impairment, activity, participation and quality of life outcome
      measures, determine the sample size, power and statistical methods for the analysis of the
      effect size for future planned randomized-controlled rehabilitation interventions in DMD.

      Aim 7: Examine the associations between interventions and incidence and severity of secondary
      conditions, achievement of disease milestones and measures of motor function and mobility.

      Aim 8: To assess the validity and responsiveness of novel clinical outcome measures in DMD,
      including the 6-minute walk test (6MWT), the 9-hole peg test (9-HPT) Egen Klassification
      Scale(EK), the North Star Ambulatory Assessment (NSAA), and quantitative key and pinch grip
      strength testing.

      Aim 9: To assess the reliability, validity and responsiveness of novel patient-reported
      outcome(PRO) measures in DMD, including the NeuroQOL and PedsQL Neuromuscular Module.

      Aim 10: To assess the clinical meaningfulness of novel objective clinical outcome measures by
      assessing their ability to predict milestones of loss of ability to stand from supine, to
      stand from a seated position, to climb stairs, to ambulate independently and to raise a hand
      to the mouth.

      AIM 11: To determine the impact of development and growth on outcome measure performance,we
      will assess physical function on a group of healthy, typically developing male children and
      adults between 6 and 30 years of age for outcome measures of motor function and strength
      including the9-HPT, 6MWT, NSAA, timed function tests and quantitative muscle strength (QMT).
      Test results from this cohort will be used to develop initial percent predicted for age
      values for these assessments.

      SNP Genotyping Study Aim

      Our goal of the proposed study is to define polygenic modifiers of disease progression, and
      also response to treatment with glucocorticoids (prednisone and deflazacort). The most common
      type of human genetic variation is the single-nucleotide polymorphism (SNP, a base position
      at which two alternative bases occur at an appreciable frequency (&gt;1%) in the population.
      SNPs are 90% of variation in the human genome. SNPs occur on the average of 1 per 1000 to
      2000 bp throughout the 3.2 billion bp of the human genome while coding region SNPs (cSNPs)
      occur on the average of 1 per 346 bp.

      Genome-wide Association Study Aim

      Our goal of the proposed study is to isolate genomic DNA and find possible correlations of
      clinical phenotypes with gene loci associated with mild vs. severe clinical presentation,
      progression, or response to steroids.

      Serum Biomarkers Study Aim

      Our goal is to discover and validate sensitive and specific serum biomarkers for DMD.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Strength and function</measure>
    <time_frame>Collected at yearly visits</time_frame>
    <description>These assessments include:
Quantitative muscle testing
Manual muscle testing
Pulmonary function testing
Functional evaluations (nine hole peg, six minute walk, North Star ambulatory assessment, Brooke and Vignos scales, Egen Klassification (EK) scale, and range of motion).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Collected at yearly visits</time_frame>
    <description>These questionnaires include:
Pediatric Quality of Life Inventory (PedsQL)
Pediatric Orthopaedic Functional Health Questionnaire of the Pediatric Orthopaedic Society of North America (POSNA)
World Health Organization Quality of Life Assessment - Brief (WHO QOL Brief)
Pediatrics and Adult Neuromuscular module Quality of Life (NeuroQOL)
Review of Systems</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Medical history assessment</measure>
    <time_frame>Collected at yearly visits</time_frame>
    <description>Outcomes on ambulation status, medication history, hospitalizations, surgeries, nutrition, fractures, and cardiac tests.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biomarkers and genetic modifiers</measure>
    <time_frame>Collected either once at any visit or each visit</time_frame>
    <description>Genotyping and Serum Biomarkers include blood/saliva collection for:
Blood collection for Genome Wide Association Study (GWAS) analysis (one time sample, any visit)
Blood or saliva collection for SNP sample (one time sample, any visit)
Blood collection for biomarker analysis (collected at each visit)</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">551</enrollment>
  <condition>Duchenne Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>Ongoing Duchenne Muscular Dystrophy (DMD) Cohort</arm_group_label>
    <description>340 patients currently enrolled participants with DMD.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>New Young Duchenne Muscular Dystrophy (DMD) Cohort</arm_group_label>
    <description>Additional 100 confirmed DMD participants aged 4-7 years old to be recruited.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Typically Developing Control Cohort</arm_group_label>
    <description>Up to 370 typically developing male children and adults aged 6-30 years old to be recruited.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples are being collected for single-nucleotide polymorphism, Genome-wide Association
      Study, and biomarker analyses.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The incidence of DMD is considered equal across racial and ethnic groups. At the start of
        the CINRG program, it was assumed by investigators that the aggregate subject populations
        of the participating US sites should closely mirror the racial and ethnic distribution of
        the US population.

        DMD is an X-linked recessive disease affecting only males. However, female carriers of the
        disease can be symptomatic due to skewed X-inactivation, a secondary genetic event. We have
        opted to study the most commonly affected population, males, to ensure subject homogeneity.
        As such, there are no outreach programs planned for women in this study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        DMD Subject Inclusion Criteria

          -  Affected subjects must be male and between the ages of 2 and 30

          -  Affected subjects between the ages of 2 and 4 must have a diagnosis of DMD confirmed
             by at least one the following OR have an older male sibling that meet at least one of
             the following criteria:

               -  Dystrophin immunofluorescence and/or immunoblot showing complete dystrophin
                  deficiency, and clinical picture consistent with typical Duchenne dystrophy OR

               -  Gene deletion test positive (missing one or more exons) in the central rod domain
                  exons 25-60) of dystrophin, where reading frame can be predicted as
                  'out-of-frame',and clinical picture consistent with typical Duchenne dystrophy.

               -  Complete dystrophin gene sequencing showing an alteration (point mutation,
                  duplication, other) that is expected to preclude production of the dystrophin
                  protein(i.e. nonsense mutation, deletion/duplication leading to a downstream stop
                  codon),with a typical clinical picture of DMD.

          -  Affected subjects between the ages of 5 and 30 must either fulfill the above criteria
             OR show evidence of a dystrophinopathy and clinical picture consistent with Duchenne
             Muscular Dystrophy

               -  Participants who have documented clinical symptoms referable to a
                  dystrophinopathy and direct support of the diagnosis by either (1) a positive DNA
                  analysis for dystrophin mutation, (2) a muscle biopsy demonstrating abnormal
                  dystrophin, or (3) an elevated CK (&gt;5X normal), and X-linked pedigree and an
                  affected family member who meets either criterion (1) or (2) as described above.

        NOTE: Determination of the appropriate clinical symptoms consistent with DMD will generally
        be the responsibility of the clinician. At a minimum this will include progressive loss of
        function, with additional consideration for other clinical features such as a
        characteristic gait, a positive Gower sign and calf pseudohypertrophy. When immunostaining
        of muscle biopsy is used to determining case definition, the clinical reviewer (site PI)
        should confirm that appropriate testing has ruled out a secondary deficiency of dystrophin.
        Affected subjects that do not exhibit the above symptoms consistent with DMD should be
        excluded.

        o Muscle weakness prevalent by 5 years of age

        - Non-affected adult subjects must be Parent(s) or legal guardian(s) of an eligible
        affected subject.

        DMD Serum Biomarker Inclusion Criteria

          -  Participants must meet eligibility criteria for the DMD phenotyping portion of this
             study

          -  For the GC-treatment response cohort, participants must initiate GC treatment within
             the first year of study participation (i.e. between their first study visit and their
             one year follow-up visit)

        DMD Subject Exclusion Criteria

        For those subjects that confirm DMD diagnosis through a clinical picture consistent with
        DMD

          -  Steroid-na√Øve subjects ambulating past the 13th birthday

          -  Steroid users ambulating past the 16th birthday

          -  Subjects/families who are unwilling or unable to comply with the protocol study
             procedures or visits

        Controls Subject Inclusion Criteria

          -  Male sex

          -  Age 6-30 years

          -  Able to comply with functional testing instructions

        Control Serum Biomarker Inclusion criteria

          -  Participants must be male

          -  Participants must be free of DMD, other neuromuscular disease, or other significant
             concomitant illness

          -  Participant must be free of glucocorticoid therapy

        Control Subject Exclusion Criteria

          -  Musculoskeletal disease

          -  Musculoskeletal injury within 6 months of enrollment

          -  Other concomitant illness that precludes functional testing in the judgment of the
             investigator or clinical evaluator

          -  Completion of enrollment for age cohort
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig McDonald, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lurie Children's Hospial</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University, St. Louis</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Children's Hospital</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tennessee</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Virginia</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Favaloro</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1434</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital at Westmead</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Children's Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alberta Children's Hospital</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2T 5C7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2J3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holland Bloorview Kids Rehab Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4G 1R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apollo Hospitals</name>
      <address>
        <city>Chennai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schneider Children's Medical Center of Israel</name>
      <address>
        <city>Petach Tikvah</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NEMO</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Silvia Children's Hospital</name>
      <address>
        <city>Gothenburg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Canada</country>
    <country>India</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Japan</country>
    <country>Puerto Rico</country>
  </removed_countries>
  <link>
    <url>http://www.cinrgresearch.org</url>
    <description>CINRG Website</description>
  </link>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 1, 2007</study_first_submitted>
  <study_first_submitted_qc>May 1, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2007</study_first_posted>
  <last_update_submitted>April 19, 2016</last_update_submitted>
  <last_update_submitted_qc>April 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

